Exact Sciences' $56 Mil. IPO Readies Firm For Colorectal Cancer Screen Trial
This article was originally published in The Gray Sheet
Executive Summary
Exact Sciences will use about $19 mil. of its $56 mil. initial public offering to fund a 5,300-patient, 40-center clinical trial evaluating genomics-based diagnostics to screen for colorectal cancer.
You may also be interested in...
Exact Data On PreGen Plus Colorectal Cancer Genomics Test Due In 2003
Exact Sciences will commercially release itsPreGen-Plus genomics-based colorectal cancer screening test technology after partnering with a large clinical reference laboratory, the firm says. A deal is expected by year-end
Exact Data On PreGen Plus Colorectal Cancer Genomics Test Due In 2003
Exact Sciences will commercially release itsPreGen-Plus genomics-based colorectal cancer screening test technology after partnering with a large clinical reference laboratory, the firm says. A deal is expected by year-end
Cancer Diagnostic Markers Top Celera's Agenda Following Sequencing Coup
Colon, pancreatic and breast cancers are initial disease areas for which Celera Genomics plans to develop diagnostic markers. In support of the effort, Celera will expand its high-throughput screening capability with the construction of a proteomics facility at the firm's Rockville, Maryland headquarters this spring.